GlassScriptPhysician profile
Ashley Trautwein
NPI 1821725433
$1,080.95
in general payments reported to CMS, 2019-2025
12 companies · $740 in 2025
The $740 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $17.91 · 2024: $323 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $988 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $988.05 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beone Medicines USA, INC. | $254.40 | 2025 | Tevimbra, Brukinsa |
| Janssen Biotech, INC. | $249.85 | 2024 | Erleada, Akeega |
| Daiichi Sankyo INC. | $124.30 | 2025 | Enhertu |
| Kite Pharma, INC. | $121.84 | 2025 | Yescarta |
| Astrazeneca Pharmaceuticals LP | $119.70 | 2025 | Datroway |
| Genzyme Corporation | $100.80 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.11 | 2024 | |
| Merck Sharp & Dohme LLC | $20.56 | 2024 | Keytruda, Welireg |
| Genentech USA, INC. | $18.71 | 2025 | Polivy |
| Acacia Pharma INC | $17.91 | 2022 | |
| Gilead Sciences, INC. | $16.00 | 2024 | |
| Exelixis INC. | $13.77 | 2024 | Cabometyx |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Trautwein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.